Giant MagnetoResistive (GMR) Sensors for Measuring Influenza Vaccine

7.项目总结/摘要 本申请的目的是鉴定自然感染和/或免疫缺陷的结果的预测标志物。 接种流感疫苗，可能适用于定义的其他传染性病原体的标志物 在RFA。我们已经组建了一个由相关传染病专家组成的多学科团队， 专家、能够获得适当患者样本的临床专家和分析专家 开发、鉴定和验证。我们将利用一种新发现的 来自Khatri实验室的签名;由Dekker和Davis小组开发的独特临床队列; 斯坦福大学的人类免疫监测中心（HIMC）使用 Fluidigm、FACS和CyTOF;以及Wang在多重检测开发方面的专业知识， 乌茨实验室。尽管超出了我们的应用范围，生物标志物特征和测定法 本发明所开发的疫苗可用于研究其他感染因子和疫苗策略， 在这个RFA机制下提供资金。我们的三个具体目标将集中在验证，应用 翻译这个签名。具体目标1是验证一组生物标志物的能力， 预测对流感疫苗接种的应答和从野生型流感病毒感染中恢复。 具体目标2将使用成熟的生物学途径表征目标1中确定的生物学途径， 先前描述的患者队列，并比较现有的生物标志物数据集， available.最后，Specific Aim 3将开发一种快速、多路复用的测定转录本的方法 使用巨磁阻（GMR）传感器，长期目标是建立一个传感器， 在测定点几分钟内测量多个转录物。我们的研究将提高我们的 了解应对流感和其他疾病的重要生物学过程 病原体，并将提供一个临床上可访问的免疫指标，快速甚至实时 对患者和疫苗进行评估。

7. Project Summary/Abstract The goal of this application is to identify predictive markers for outcomes of natural infection and/or vaccination with influenza, markers that are perhaps applicable to other infectious agents defined in the RFA. We have assembled a multi-disciplinary team composed of relevant infectious disease experts, clinical experts with access to appropriate patient samples, and experts in assay development, qualification, and validation. We will take advantage of a newly discovered predictive signature from the Khatri lab; unique clinical cohorts developed by the Dekker and Davis groups; Stanford’s Human Immune Monitoring Center (HIMC) for analysis of blood samples using Fluidigm, FACS and CyTOF; and expertise in multiplexed assay development by the Wang and Utz labs. Although beyond the scope of our application, the biomarker signature and the assays developed herein can be used to study other infectious agents and vaccine strategies that will be funded under this RFA mechanism. Our three specific aims will focus on the validation, application and translation of this signature. Specific Aim 1 is to validate a panel of biomarkers for their ability to predict response to influenza vaccination and recovery from wild-type influenza virus infection. Specific Aim 2 will characterize biological pathways identified in Aim 1 using well-established and previously described patient cohorts, and to compare the existing biomarker datasets that are available. Finally, Specific Aim 3 will develop a rapid, multiplexed assay for measuring transcripts using Giant MagnetoResistive (GMR) Sensors, with a long term goal to build a sensor capable of measuring multiple transcripts within minutes at point-of-assay. Our studies will enhance our understanding of the important biological processes involved in response to influenza and other pathogens, and will provide a clinically accessible immune metric for rapid or even real-time evaluation of patients and vaccines.